Importance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by ultraviolet B in neonatal hyperbilirubinemia

Kyohei Sumida, Makiko Kawana, Emi Kouno, Tomoo Itoh, Shuhei Takano, Tomoya Narawa, Robert H. Tukey, and Ryoichi Fujiwara

School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JAPAN (K.S., M.K., E.K., T.I., S.T., T.N., R.F.)

Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California, United States of America (R.H.T.)
Running title: UGT1A1 is expressed and induced by UVB in skin

* Corresponding author:
Ryoichi Fujiwara, Ph.D.
School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JAPAN, fujiwarar@pharm.kitasato-u.ac.jp, +81-3-5791-6249.

Number of text pages: 38
Number of figures: 8
Number of references: 46
Number of words in the Abstract: 228
Number of words in the Introduction: 539
Number of words in the Discussion: 1410

Abbreviations: UGT, UDP-glucuronosyltransferase; UV, ultraviolet; CYP, cytochrome P450; FICZ, 6-formylindolo[3,2-b]carbazole; Q-RT-PCR, quantitative reverse transcription-PCR; HPLC, high performance liquid chromatography; AhR, aryl hydrocarbon receptor; HaCaT, human skin keratinocyte; hUGT1, humanized UGT1.
Abstract

UDP-glucuronosyltransferase (UGT) 1A1 is the sole enzyme that can metabolize bilirubin. Human infants physiologically develop hyperbilirubinemia due to inadequate expression of UGT1A1 in the liver. While phototherapy using blue light is effective in preventing jaundice, sunlight has also been suggested, but without conclusive evidence, to reduce serum bilirubin levels. We investigated the mRNA expression pattern of human UGT1A1 in human skin, human skin keratinocyte (HaCaT) cells, and skin of humanized \textit{UGT1} mice. The effects of ultraviolet B (UVB)-irradiation on the expression of UGT1A1 in the HaCaT cells were also examined. Multiple UGT1A isoforms including UGT1A1 were expressed in human skin and HaCaT cells. When HaCaT cells were treated with UVB-exposed tryptophan, UGT1A1 mRNA and activity were significantly induced. The treatment of the HaCaT cells with 6-formylindolo[3,2-b]carbazole (FICZ), which is one of the tryptophan derivatives formed by UVB, resulted in an induction of UGT1A1 mRNA and activity. In neonates the expression of UGT1A1 was greater in the skin, while in adults UGT1A1 was mainly expressed in the liver. Treatment of humanized \textit{UGT1} mice with UVB resulted in a reduction of serum bilirubin levels, along with increased UGT1A1 expression and activity in the skin. Our data revealed a protective role of UGT1A1 expressed in the skin against neonatal hyperbilirubinemia.
Sunlight, a natural and free source of light, makes it possible to treat neonatal jaundice, while allowing mothers to breast-feed neonates.
Introduction

UDP-glucuronosyltransferases (UGTs; EC 2.4.1.17) are a family of membrane-bound enzymes that catalyze the transfer of the glucuronic acid moiety of UDP-glucuronic acid to a large number of endogenous and exogenous compounds (Dutton, 1980). Human UGTs are divided into two distinct families, UGT1 and UGT2, on the basis of evolutionary divergence and homology (Mackenzie et al., 2005). The UGT1 gene is located on chromosome 2q37 and produces nine functional enzymes (UGT1A1, UGT1A3-UGT1A10) by exon sharing (Ritter et al., 1992). The UGT2A and UGT2B genes are located on chromosome 4q13, encoding three and seven functional proteins, respectively. The UGT2A1 and UGT2A2 are formed by differential splicing of variable first exons and common exons 2 to 6, likely the UGT1A gene (Mackenzie et al., 2005). Meanwhile, UGT2A3 and each UGT2B are encoded by individual genes (Mackenzie et al., 2005). Each UGT enzyme expresses in a tissue-specific manner and exhibits substrate specificity (Tukey and Strassburg, 2000).

Bilirubin is an end product of heme catabolism, formed by the breakdown of red blood cells. Bilirubin is bound to serum proteins and is taken up by the liver where it is conjugated by UGT1A1 with glucuronic acid. The conjugated bilirubin is excreted into the small intestine via the bile duct (Kamisako et al., 2000). Because UGT1A1 is the sole bilirubin conjugating enzyme (Bosma et al.,
1994), its genetic polymorphism or inhibition of UGT1A1 activity by agents such as coadministered drugs can cause increased serum levels of unconjugated bilirubin (Mackenzie et al., 2000; Danoff et al., 2004). The unconjugated bilirubin crosses the blood-brain barrier and accumulates in the brain causing neurotoxicity. Newborn infants commonly develop mild hyperbilirubinemia, which is called physiological jaundice. Although jaundice usually disappears within a few weeks, severe hyperbilirubinemia can be severe and cause kernicterus (Gourley, 1997). To prevent occurrences of kernicterus, infants who develop severe hyperbilirubinemia are often treated with phototherapy to directly reduce plasma bilirubin levels by isomerizing bilirubin. However, there is a limitation with phototherapy requiring mothers not to breast-feed; additionally, it requires conventional phototherapy units which are not available in some countries.

Sunlight has been suggested as an alternative way to treat neonatal jaundice (Salih, 2001). It was demonstrated that sunlight was more effective in isomerizing bilirubin than phototherapy (Salih, 2001). Furthermore, it was shown that ultraviolet (UV)-B in sunlight photo-oxidizes L-tryptophan, activating the aryl hydrocarbon receptor (AhR) in the skin (Wincent et al., 2009). Because the expression of human UGT1A1 is regulated by various nuclear receptors, including AhR (Yueh et al., 2003), it is hypothesized that UGT1A1 expressed in the skin might play an important role in sunlight-induced reduction of serum bilirubin, since the skin covers a surface area of approximately
1.7 m² in an average adult body and 0.2 m² in a 3 kg newborn infant, and receives about one-third of the circulating blood. However, little is known about the expression pattern of UGT1A1 in the human skin. To investigate the protective role of UGT1A1 in the skin against neonatal hyperbilirubinemia, we examined mRNA expression patterns of human UGT1 family enzymes in human skin, human skin keratinocyte (HaCaT) cells, and in recently developed humanized UGT1 (hUGT1) mice (Fujiwara et al., 2010). We also examined the effects of UVB-irradiation on the expression of human UGT1 in the HaCaT cells.

Materials and Methods

Chemicals and Reagents

L-tryptophan was purchased from Sigma–Aldrich (St Louis, MO). FICZ and 7-ethoxyresorufin were purchased from BIOMOL (Enzo Life Sciences, Plymouth Meeting, PA). HaCaT cells were purchased from CLS Cell Lines Service (Eppelheim, Germany). The human total skin and liver RNA was purchased from Agilent Technologies (Santa Clara, CA) and Applied StemCell (Sunnyvale, CA). Primers were commercially synthesized at Invitrogen (Carlsbad, CA). PrimeSTAR DNA polymerase was purchased from TaKaRa Bio (Shiga, Japan) and Ssofast Evagreen Supermix was obtained from BioRad (Hercules, CA). UGT1A1 Supersomes and human liver microsomes were purchased from
BD Gentest (Woburn, MA). Anti-human UGT1A antibody (B-4) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals and solvents were of analytical grade or the highest grade commercially available.

Cell culture and chemical treatments

HaCaT cells have differentiation characteristics similar to those of normal human keratinocytes even though they are immortal and genetically abnormal (Schoop et al. 1999). HaCaT cells were grown in Dulbecco's modified Eagle's medium supplemented with 1 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM nonessential amino acids (NEAA), 2 mM Gluta-MAX™-I, and 10% fetal bovine serum with 5% CO₂ at 37°C. Before the chemical treatment, HaCaT cells (passage 40-45) were seeded into six-well plates at 1 × 10⁶ cells/well. After 72 hours, the culture medium was changed to a DMEM medium containing 0.1 to 50 nM FICZ, irradiated tryptophan, or vehicle and subsequently cells were maintained for 6 hours until harvesting. FICZ was dissolved in dimethyl sulfoxide with a final concentration in the medium of less than 0.1%.

Animals and treatments

Tg(UGT1A1*28)Ugt1−/− (hUGT1) mice were developed previously in a C57BL/6 background (Fujiwara et al., 2010). All animals received food and water ad libitum, and mouse handling and
experimental procedures were conducted in accordance with our animal care protocol, which has
been approved by Kitasato University. A day after 60 min irradiation of three-day old male hUGT1
mice to UVB using a UV lamp (irradiation wavelength: 302 nm, 3UV-38 3UV Lamp; UVP Inc.,
Upland, CA) at 15 cm distance from skin surface, blood and tissues were collected. For tissue
collections, male mice were anesthetized by diethyl ether inhalation, and the liver was perfused with
ice-cold 1.15% KCl. The skin and liver were rinsed in cold 1.15% KCl and stored at −80°C.

**Bilirubin measurements**

Blood was obtained from the submandibular vein and centrifuged at 2000×g for 5 minutes.

Serum samples (10 μL) were measured for total serum bilirubin using a Bilirubinometer (B-105N,
Erma, Tokyo, Japan). For each serum sample, the bilirubin value was measured three times and the
mean value was used for data analysis. To avoid hemolysis of the serum and photolysis of the
bilirubin, the serum samples were analyzed promptly after collection of blood.

**Semi-quantitative and quantitative (Q) reverse transcription (RT)-PCR**

Total RNA was extracted from HaCaT cells with Trizol reagent (Invitrogen). The cDNA was
synthesized from total RNA using ReverTra Ace (TOYOBO, Osaka, Japan) according to the
manufacturer’s protocol. A 1-μl portion of the reverse-transcribed mixture was added to PCR
mixtures (25 μl). The amplification was performed by denaturation at 98°C for 10 seconds, annealing
at 60°C for 10 seconds, and extension at 72°C for 20 seconds for 20 cycles for Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and for 35 cycles for UGTs. The sequences of primers used in the present study are as follows: CYP1A1-Forward: 5'-GGC TGG CCT ATG TGG TCT AA-3':
Reverse: 5'-ATG TGG CCC TGT TTT ACC TG-3'. Primers for human UGTs and GAPDH were developed previously (Nakamura et al., 2008). The PCR products (20 µl) were analyzed by electrophoresis with 2% agarose gel and visualized by ethidium bromide staining. Expression of GAPDH mRNA was used as an internal control for the cDNA quantity and quality. Q-RT-PCR was performed with Ssofast Evagreen Supermix, and the reactions were run in a CFX96™ Real-Time PCR Detection System (BioRad).

Irradiation of L-tryptophan

Aqueous solutions of L-tryptophan (100 mL of 80 µM) were irradiated with UVB lamps (BLE-1T158, Spectronics Corp, Westbury, NY) for 5 to 60 minutes at a distance of 30 cm (1.4 mW/cm²) at room temperature. To eliminate UVC wavelengths, a UVC filter (CLAREX S-0, Nitto Jushi Kogyo, Tokyo, Japan) was used while L-tryptophan was being irradiated. Following irradiation, the tryptophan solutes were protected from light and were immediately used for the cell treatment. HaCaT cells were treated for 6 hours with irradiated L-tryptophan by adding a 1-mL portion of irradiated L-tryptophan to the culture medium.
7-Ethoxy-resorufin-O-deethylase (EROD) activity

EROD activity in the HaCaT cells was determined as follows. Non-treatment or chemically treated HaCaT cells in 6-well plates were washed twice with 1 mL of Hank’s balanced salt solution (HBSS; 145 mM NaCl, 3 mM KCl, 1 mM CaCl₂, 0.5 mM MgCl₂, 5 mM D-glucose, 5 mM HEPES pH 7.4). After the cells were pre-incubated with 1.5 mL of HBSS for 10 minutes at 37°C, the HBSS solution was replaced with 2 mL of HBSS containing 7-ethoxy-resorufin at a final concentration of 2 µM and cells were then incubated for 30 to 120 minutes at 37°C. The reaction was stopped by adding 2 mL of ice-cold methanol. The cells were then sonicated for 5 minutes. After the sonication, the cell solution was centrifuged at 10,000 g for 10 minutes at 4°C and a 50 µL-portion of the supernatant was subjected to high performance liquid chromatography (HPLC) to quantitate the formation of resorufin.

HPLC conditions

The formation of resorufin was determined by the HPLC system with a LC-10AD pump (Shimadzu, Kyoto, Japan), a FP-2020 fluorescence detector (JASCO, Tokyo Japan), a SIL-10A autosampler (Shimadzu), a SLC-10A system controller (Shimadzu) and a Mightysil RP-18 GP column (4.6 × 150 mm, 5 µm; Kanto Chemical, Tokyo, Japan). The mobile phase was 25 mM phosphate buffer (pH 7.0)-methanol (64:36, v/v) and the flow rate was 0.8 mL/min. Detection was
accomplished with a fluorescence detector at 560-nm excitation and 585-nm emission. Quantification of resorufin was carried out by comparing the HPLC peak area to that of the authentic standard.

**Estradiol 3-O-glucuronidation**

Skin microsomes were prepared using the following procedure. Skin was homogenized in three volumes of Tris-buffered saline [25 mM Tris-HCl buffer (pH 7.4), 138 mM NaCl, and 2.7 mM KCl]. The homogenate was centrifuged at 10,000 × g for 30 min at 4°C, and the supernatant was collected. The supernatant was centrifuged at 105,000 × g for 60 min at 4°C, and the pellet was suspended in the same buffer and used as the microsomal fraction. Protein concentrations of microsomal fractions were measured by the Bradford method using BSA as a standard (Bradford, 1976). Estradiol 3-O-glucuronide formation was determined according to the method of Fujiwara et al. (2007) with slight modifications. Briefly, a typical incubation mixture (200 μl of total volume) contained 50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 2 mM UDPGA, 50 μg/ml alamethicin, 0.25-2.0 mg/ml microsomes, and 10 μM estradiol. The reaction was initiated by the addition of UDPGA after a 3-min preincubation at 37°C. After incubation at 37°C for 90 min, the reaction was terminated by addition of 200 μl of cold methanol. After removal of the protein by centrifugation at 12,000 g for 5 min, a 50-μl portion of the sample was subjected to HPLC. The condition of HPLC analysis was described previously (Fujiwara et al., 2007).
SDS/PAGE and immunoblotting

Microsomal fractions were prepared as described above. Ten to 150 \( \mu \)g of microsomal protein were separated on 4–12% NuPAGE Bis-Tris polyacrylamide gels (Invitrogen). Immunoblots with antibodies to UGT1A were performed as previously outlined (Fujiwara et al., 2010).

Statistical analyses

Statistical significances were determined by analysis of variance followed by Dunnett’s test or unpaired Student’s t test. A value of \( P < 0.05 \) was considered statistically significant.

Results

Identification of UGT isoforms expressed in the human skin

While the skin is one of the body’s largest primary barriers to the environment, the expression pattern of detoxification enzymes such as the UGTs in human skin has not yet been quantitated. In this study, the expression levels of human UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 in human keratinocyte HaCaT cells were examined using human UGT1A isoform specific primers (Nakamura et al., 2008). The semi-quantitative RT-PCR revealed that a wide variety of UGT1A isoforms, UGT1A1, UGT1A3, UGT1A4, and UGT1A8, were expressed in the HaCaT cells (Fig. 1A). We further determined the expression
patterns of human UGT1A mRNA in human skin from two different donor samples. In addition to
the expression of UGT1A1, UGT1A3, UGT1A4, and UGT1A8, we observed that UGT1A7 and
UGT1A10 were highly expressed in human skin (Fig. 1B).

**Induction of UGT1A1, UGT1A8, and CYP1A1 by irradiated L-tryptophan in HaCaT cells**

It has been reported that UVB irradiation photo-oxidizes tryptophan in the skin and produces
FICZ, which is an agonist of AhR (Wincent et al., 2009). To understand whether UVB irradiation of
L-tryptophan could result in an activation of AhR in the HaCaT cells, we irradiated 80 µM of
L-tryptophan, comparable to the concentration of tryptophan in human blood (Suzuki et al., 2010),
with UVB for up to 60 minutes followed by treatment of HaCaT cells. Because induced EROD
activity reflects AhR dependent induction of CYP1A1 activity, we first determined EROD activity
in control and irradiated L-tryptophan-treated HaCaT cells by quantitating the formation of
resorufin in the culture medium. HaCaT cells were exposed for 6 hours to irradiated L-tryptophan
for 60 minutes. The amount of formed resorufin was approximately four to five times greater in the
irradiated L-tryptophan-treated HaCaT cells ($\text{CL}_{\text{int}} = 1.34 \mu\text{L/min/mg protein}$) than of that in the
control cells ($\text{CL}_{\text{int}} = 0.28 \mu\text{L/min/mg protein}$) (Fig. 2A), indicating that irradiated L-tryptophan
does induce CYP1A1. To understand the effects of irradiation time on the inducibility of
L-tryptophan for CYP1A1, HaCaT cells were exposed for 6 hours to L-tryptophan that had been
irradiated for 5, 15, and 60 min, respectively, and the expression level of CYP1A1 mRNA was
determined by Q-PCR. CYP1A1 was induced 5-fold when HaCaT cells were treated with
L-tryptophan that had been irradiated for 60 min (Fig. 2B), which was comparable to the induced
EROD activity (Fig. 2A). Interestingly, the level of CYP1A1 induction was even higher when
HaCaT cells were treated with L-tryptophan that was irradiated for 5 min (Fig. 2B). Since UGT1A1
and UGT1A8 play important roles in the detoxification of neurotoxic bilirubin and carcinogens, we
next investigated the inducibility of UVB-irradiated L-tryptophan on UGT1A1 and UGT1A8 in
human skin HaCaT cells. The induction pattern of UGT1A1 in HaCaT cells with UVB-irradiated
L-tryptophan was very similar to that of CYP1A1 (Fig. 2C). With 5-minute UVB-irradiated
L-tryptophan, UGT1A1 was induced approximately 4-fold, while it resulted in a 10-fold induction
of UGT1A8 (Supplemental Fig. 1).

**Induction of CYP1A1, UGT1A1, and UGT1A8 in the FICZ-treated HaCaT cells**

To investigate the direct effects of FICZ on the expression of UGT1A1 and UGT1A8, as well
as CYP1A1, HaCaT cells were treated with FICZ and RT-PCR was carried out for these genes. The
FICZ treatment of HaCaT cells in our study showed a dose-dependent induction of CYP1A1 (Fig.
3A). Our semi-quantitative RT-PCR revealed that UGT1A1 and UGT1A8 were induced by 50 nM
FICZ in the HaCaT cells (Supplemental Fig. 2). Although UGT1A7 and UGT1A10 were slightly
expressed in non-treatment HaCaT cells (Fig. 1A), clearer bands of those isoforms were observed in
the FICZ-treated HaCaT cells (Supplemental Fig. 2). We further conducted a Q-RT-PCR analysis
of UGT1A1, UGT1A4, and UGT1A8 in control and FICZ-treated HaCaT cells. In the FICZ
treatment, UGT1A1 and UGT1A8 were induced 2- and 3.7-fold, respectively, compared to control
cells (Fig. 3B). Similar to CYP1A1, UGT1A1 was also induced by FICZ dose-dependently (Fig.
3C). On the other hand, UGT1A4 was not induced by 50 nM FICZ (Fig. 3B). The data indicates
that not only CYP1A1 but also multiple UGT1A isoforms, especially UGT1A1 and UGT1A8, were
induced by FICZ in the human skin cells.

**Induction of estradiol 3-O-glucuronidation activities by UVB and FICZ in HaCaT cells**

We further investigated whether the treatment of the HaCaT cells with UVB-exposed
tryptophan and FICZ results in an increase of UGT activities. To obtain a large enough amount of
the microsome fraction from HaCaT cells to conduct UGT enzyme assays, HaCaT cells were
cultured in fifteen 150-mm dishes for each group. After the cells were treated for 24 hours with
UVB-exposed tryptophan or 50 nM FICZ, the cells were harvested and the microsomes were
prepared using the method described earlier. Estradiol 3-O-glucuronidation is one of the metabolic
reactions selectively metabolized by UGT1A1. The estradiol 3-O-glucuronidation activity was 1.9
pmol/min/mg in the microsomes prepared from the control HaCaT cells (Fig. 4). The treatment of
the cells with UVB-exposed tryptophan and FICZ increased microsomal activity to 5.5 pmol/min/mg and 3.9 pmol/min/mg, respectively. The fold induction of the UGT activity was correlated with the induction level of UGT1A1 mRNA (Fig. 2 and 3), indicating that UVB or FICZ similarly induced both UGT1A1 mRNA and activity in the HaCaT cells.

Comparison of the UGT1A1 expression in the skin and liver

It is known that UGT1A1 is expressed in the liver. Therefore, the liver has been considered the main tissue for bilirubin metabolism in adults. In human infants, however, the liver expresses inadequate UGT1A1 (Coughtrie et al., 1988), causing the development of physiological hyperbilirubinemia. In agreement with previous reports, human adult UGT1A1 is highly expressed in the liver – 20,000 fold higher than in skin (Fig. 5A). To understand the importance of UGT1A1 expressed in the skin in neonatal hyperbilirubinemia, we determined and compared the UGT1A1 expression levels in the skin and liver of neonatal hUGT1 mice. While in adults UGT1A1 was mainly expressed in liver (Fig. 5A), in neonates the expression of UGT1A1 was greater in the skin (Fig. 5B). At 3 days after birth, the expression of UGT1A1 in the skin was 2.5-fold higher than that in the liver. At 14 days after birth, which is when hUGT1 mice develop severe jaundice (Fujiwara et al., 2010), the expression of UGT1A1 in the skin was 4.5-fold greater than that in the liver. These
results indicate that in neonatal life, UGT1A1 expressed in the skin might be important in reducing serum bilirubin to prevent the onset of kernicterus.

**Effects of UVB irradiation on UGT1A1 expression and activity in neonatal hUGT1 mice**

To further investigate whether UVB irradiation results in an induction of skin UGT1A1 in vivo, three-day old hUGT1 mice were exposed to UVB and then serum bilirubin levels were determined, as well as UGT1A1 mRNA, protein, and activity in the skin. At 4 days after birth, hUGT1 mice had on average 9.2 mg/dL total serum bilirubin (TSB). When 3-day old hUGT1 mice were exposed to UVB for 60 min, their TSB levels decreased to 6.2 mg/dL at 4 days after birth, which was 24 hours after the UVB treatment (Fig. 6). Because bilirubin is solely metabolized by UGT1A1, this result suggests that the UVB might have induced UGT1A1 expression in the skin to accelerate bilirubin metabolism. Q-PCR analysis revealed that the UGT1A1 level in the skin of UVB-treated mice was 3-fold higher than the level in the skin of non-treated mice (Fig. 7A). To examine the effect of the UVB treatment on the UGT1A1 protein expression in the skin, skin microsomes were prepared from the control and UVB-treated mice and were subjected to immunoblot analysis. Although faint, the expression of UGT1A protein in the skin from hUGT1 mice was observed in the immunoblot analysis (Fig. 7B, lane 3-5). With the 60 min UVB treatment of the mice, UGT1A protein expressions increased (Fig. 7B, lane 6-8) and the level was more than
3-fold compared to the level in control mice (Fig. 7C). UGT1A1 activities in the skin microsomes were further assessed to examine whether the induced UGT1A1 mRNA/protein expression resulted in an increase in functional UGT1A1. The estradiol 3-O-glucuronide formation rate was 1.0 pmol/min/mg and 1.5 pmol/min/mg in the skin microsomes from control and UVB-treated hUGT1 mice, respectively (Fig. 8), indicating that UGT1A1 activities in the skin were induced with UVB. It was further demonstrated that the UVB treatment of the mice only induced UGT1A1 in the skin (Supplemental Figure 3). This finding indicates that the reduction in serum bilirubin levels in the UVB-treated mice can be mainly attributed to the increased expression of UGT1A1 in the skin.

Discussion

Because the liver plays a crucial role in the metabolism of endogenous and exogenous compounds such as drugs, environmental carcinogens, and hormones, the expression pattern of phase I and phase II drug-metabolizing enzymes in the liver has been widely analyzed (Tukey and Strassburg, 2000; Shimada et al., 1994). Meanwhile, extrahepatic tissues such as the skin, the small and large intestine, the kidneys, and the lungs also contribute to the metabolic process of a wide variety of chemicals. Due to the fact that the skin covers a surface of approximately 1.7 m² in an average adult and receives about one-third of the blood supply, the skin plays an important role in
the metabolic clearance and metabolic activation of endogenous and exogenous compounds. While
UGT is involved in the detoxification of various compounds, a previous report indicated that UGT
RNA could not be identified in human skin (Ritter et al., 1992), even though Peters et al. originally
determined the presence of the bilirubin-UGT isoform and 4-nitrophenol-UGT isoform(s) in human
skin (Peters et al., 1987). However, *in vitro* and *in vivo* analyses subsequently identified the
expression of UGT in human skin (Vecchini et al., 1995; Ademola et al., 1993; Moss et al., 2000).
A recent publication by Götz et al. also showed glucuronidation activity toward
4-methylumbelliferone in human skin microsomes, which indicates the presence of functional UGT
enzymes in the skin (Götz et al., 2012). Whereas the expression pattern of human CYPs in the skin
has already been determined (Bergström et al., 2007), the expression pattern of human UGTs in the
skin had not been fully examined. In the present study, we performed RT-PCR and real-time
RT-PCR from HaCaT cells and human skin, finding that various UGT1A family enzymes,
including UGT1A1, UGT1A3, UGT1A4, UGT1A7, UGT1A8, and UGT1A10, were expressed (Fig.
1). This indicates that while the HaCaT cell line is a spontaneously immortalized human
keratinocyte cell line, the UGT1 gene expression pattern in HaCaT cells is very similar to that in
actual human skin.
Neonatal jaundice is a condition marked by high levels of serum bilirubin. Although it is generally treatable with phototherapy or phenobarbital treatment, it has a risk of causing permanent brain damage, kernicterus. The metabolic pathway of bilirubin has been reported as follows: 1) Transport of bilirubin into the liver by organic anion transporting polypeptide (Oatp1b2 in mice and OATP1B1 and 1B3 in humans) and/or by diffusion; 2) Conjugation with a glucuronic acid by UGT1A1 in the liver; 3) Transport of the glucuronide into bile by multidrug resistance-associated protein 2 (MRP2); 4) Excretion into intestine; 5) Excretion into feces as parent compound or intestinal metabolites (Kamisako et al., 2000; Kikuchi et al., 2002). However, previous studies have suggested the contribution of extrahepatic tissues to bilirubin metabolism in humans (Medley et al., 1995). More recently using hUGT1 mice, where the expression of hepatic UGT1A1 is low, extrahepatic expression of UGT1A1 in the GI tract was shown to prevent the onset of kernicterus (Fujiwara et al., 2012). During neonatal development, UGT1A1 gene expression was greater in the skin than the level in the liver (Fig. 5). UGT1A1 expression and activity were even induced by UVB exposure of HaCaT cells, possibly by activating AhR (Fig. 3 and 4). Our in vivo study with hUGT1 mice also showed that UVB exposure of the mice caused increased UGT1A1 expression in the skin, resulting in reduction of serum bilirubin levels (Fig. 6-8). While almost 100% of UVC (190-280 nm) is filtered by the ozone layer and does not reach the earth, a certain amount of UVB
(280-315 nm) and about 95% of UVA (315-400 nm) penetrate the ozone layer, reaching the surface of the earth. Therefore, the expression of UGT1A1 and its induction by UVB might be the mechanism underlying sunlight-induced reduction of serum bilirubin in human infants. Interestingly, the UV treatment only induced UGT1A1 in the skin (Supplemental Figure 3), which is in contrast to a finding that a treatment of hUGT1 mice with 2,3,7,8,-tetrachlorodibenzo-p-dioxin – a ligand of AhR – resulted in an increase of UGT1A1 in the liver and small intestine (Fujiwara et al., 2010). At three to five days after birth, the serum bilirubin level in humanized UGT1 mice is on average 10 mg/dL lower than that in Ugt1a1 KO mice (Fujiwara et al., 2010), indicating that UGT1A1 expressed in hUGT1 mice can clear 10 mg/dL serum bilirubin from the body. In the current study, the serum bilirubin level in UVB-treated hUGT1 mice was 3 mg/dL lower than that in control hUGT1 mice. This indicates that clearance capacity was increased by 30% with the UVB exposure.

It has been demonstrated that CYP1A1 does oxidize bilirubin, contributing to metabolize bilirubin (Zaccaro et al., 2001). To investigate the role of CYP1A1 in the skin in contributing to the elimination of bilirubin following UV irradiation of skin, bilirubin was incubated with skin microsomes from the UV-treated hUGT1 mice in the presence and absence of the NADPH generating system. The residual concentration of bilirubin in the incubation mixture was similar between the two samples (data not shown), indicating that CYPs did not metabolize bilirubin that
much in the *in vitro* experimental condition with skin microsomes. However, this does not eliminate the possibility that CYP1A1 contributes to the elimination of bilirubin following UV irradiation of skin in human neonates. While a more complete quantification of serum bilirubin conjugation and degradation products will further support our conclusions, there is some technical difficulty in conducting such experiments, since we can only obtain up to 10 µL serum from neonatal mice, which allows us to conduct one bilirubin assay with a Bilirubinometer. We have tried to quantitate direct and indirect bilirubin contents in the serum on a small scale; however, it did not produce reproducible values due to the inadequate volume of serums used in the assay, in which 150 µL serum was required by the manufacturer’s protocol.

Clinical intervention to treat episodes of severe hyperbilirubinemia calls for extended phototherapy treatment or even blood transfusion. While exchange transfusions using the umbilical vein are now becoming extinct, phototherapy also has disadvantages. Increased insensible water loss, skin rashes, pyrexia, decreased maternal-infant interaction, and lack of visual sensory input are potential disadvantages of this treatment (Wananukul et al., 2002; Kumar et al., 2010; Tan et al., 1977). Breast-feeding has been implicated in short- and long-term health benefits to growing children, including reduced risks of infectious diarrhea, necrotizing enterocolitis (Agostoni et al., 2009), type I and type II diabetes (Mayer et al., 1988; Pettitt et al., 1997), reduced frequency of food
allergies (Saarinen et al., 1995), and a protective effect on the development of early-onset inflammatory bowel disease (Barclay et al., 2009) – although breast milk can also potentially induce the risk for kernicterus (Newman and Gross, 1963). Therefore, treatment of newborn infants with sunlight might be the ideal therapeutic method, because it allows continuous breast-feeding. Clinical data would be needed to confirm the protective role of skin UGT1A1 against human neonatal hyperbilirubinemia in vivo.

Interestingly, we also observed the expression of UGT1A8 in human skin and its induction by UVB in HaCaT cells (Fig. 1, and Supplemental Fig. 1 and 2). While CYP1A1 is involved in the activation of benzo[a]pyrene (Nelson et al., 2004), which is one of the polycyclic aromatic hydrocarbon compounds and is involved in the UVB-associated development of skin cancer, UGT1A8 is involved in the detoxification of benzo[a]pyrene (Fang et al., 2002; Zheng et al., 2002). Therefore, UGT1A8 expressed in the skin might play a protective role against the development of skin cancer by accelerating the metabolism of benzo[a]pyrene. AhR is the sole transcription factor that can regulate the expression of CYP1A1. On the other hand, multiple transcription factors such as pregnane X receptor and constitutive androstane receptor, and the peroxisome proliferator-activated receptor-α, in addition to AhR, can regulate human UGT gene expression (Chen et al., 2005; Yueh et al., 2003; Sugatani et al., 2005; Seneko-Effenberger et al., 2007).
Therefore, upregulation of benzo[a]pyrene-metabolizing UGTs by activation of those UGT-specific transcription factors with natural substances such as coumarins and flavonoids might result in a decrease in the development of skin cancer (Chlouchi et al., 2007).

In conclusion, this is the first study to determine the expression pattern of human UGT1A-family enzymes in human skin. Our data revealed a protective role of UGT1A1 expressed in the skin against neonatal hyperbilirubinemia. Sunlight, a natural and free source of light, makes it possible to treat neonatal jaundice without phototherapy units, while allowing mothers to breast-feed neonates.
Authorship Contributions:

Participated in research design: Itoh, Tukey, and Fujiwara.

Conducted experiments: Sumida, Kawana, Kouno, Takano, Narawa, and Fujiwara.

Performed data analysis: Sumida, Kawana, and Fujiwara.

Wrote or contributed to the writing of the manuscript: Itoh, Tukey, and Fujiwara.
References


Chen S, Beaton D, Nguyen N, Senekoe-Effenberger K, Brace-Sinnokrak E, Argikar U, Remmel RP,


Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y.
Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. *J Gastroenterol.* 35:659-664.


Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and...


FOOTNOTES

Funding for this work was provided by US Public Health Service Grants [P42ES010337 and GM100481]. This work was also supported by a Grant-in-Aid for Research Activity Start-up [24890224]; and a Kitasato University Research Grant for Young Researchers.
**Figure Legend**

**Figure 1. The expression pattern of human UGT1A-family enzymes in human skin.** A 1-µl portion of cDNA reverse-transcribed from HaCaT total RNA (A) or human skin RNA (B) was added to PCR mixtures (25 µl). The PCR products (20 µl) were analyzed by electrophoresis with 2% agarose gel and visualized by ethidium bromide staining. M, 100 bp ladder marker.

**Figure 2. The effect of UVB-irradiated L-tryptophan on CYP1A1 and UGT expression in HaCaT cells.** A 1-mL portion of UVB-irradiated L-tryptophan was added to the cell culture medium and cells were treated for 6 h. EROD activity in the UVB-irradiated L-tryptophan-treated HaCaT cells was determined by incubating the cells with 7-ethoxy-resorufin for 30, 60, 120, and 180 min. Formed resorufin was quantified by HPLC. Filled circles were from non-treatment cells and open triangles were from UVB-irradiated L-tryptophan-treated cells (A). The HaCaT cells were treated for 6 h with L-tryptophan that had been irradiated for 0, 5, 15, and 60 min with UVB. Total RNA was isolated from the HaCaT cells and Q-PCR was carried out for CYP1A1 (B) and UGT1A1 (C). C, control. *, $P < 0.05$, compared with the expression in the control HaCaT cells.
Figure 3. The effect of FICZ treatment on CYP1A1 and UGT expression in HaCaT cells. Total RNA was isolated from HaCaT cells that were treated with FICZ for 6 h. Complementary DNA was synthesized, and then quantitative RT-PCR was carried out for human CYP1A1 (A) and UGT (B). Concentration-dependent effects of FICZ on UGT1A1 expression was also analyzed (C). Each column is the mean ± S.D. of three independent determinations. C, control. *, P < 0.05, compared with the expression in the control HaCaT cells.

Figure 4. Effects of UVB- and FICZ treatments on the UGT1A1 activity in the HaCaT cells. Microsomes were prepared from the HaCaT cells and estradiol 3-O-glucuronide formation was measured. Error bars show SD, n = 3. **, P < 0.01; *, P < 0.05.

Figure 5. The expression of UGT1A1 in the skin and liver. Complementary DNA was synthesized from total skin and liver RNA from adult human (A) or 3-day- and 14-day-old hUGT1 mice (B), and quantitative RT-PCR was carried out for human UGT1A1. Each column is the mean ± S.D. of three independent determinations.
Figure 6. Serum bilirubin levels of control and UVB-treated hUGT1 mice. Blood was collected from 4-day old hUGT1 mice and serum bilirubin levels were measured. Error bars show SD, n = 8.

*, P < 0.05.

Figure 7. Effects of UVB-treatments on the expression of UGT1A1 in the skin of hUGT1 mice. RNA was isolated from the skin of control and UVB-treated hUGT1 mice and quantitative RT-PCR was carried out for human UGT1A1 (A). Microsomes from the skin were prepared and subjected to immunoblot analysis with anti-UGT1A antibodies. As the positive control, UGT1A1 Supersomes (10 µg) and human liver microsomes (10 µg) were also subjected to immunoblotting (B). The density of the bands was quantified using ImageJ software (Wayne Rasband, NIH). Error bars show SD, n = 3. *, P < 0.05.

Figure 8. Effects of UVB-treatments on the UGT1A1 activity in the skin of hUGT1 mice. Microsomes from the skin were prepared and estradiol 3-O-glucuronide formation was measured.

Error bars show SD, n = 3. *, P < 0.05.
Figure 1

A

M

HaCaT cells

UGT1A1 UGT1A3 UGT1A4 UGT1A5 UGT1A6 UGT1A7 UGT1A8 UGT1A9 UGT1A10 GAPDH

B

M

Human skin (Donor A)

UGT1A1 UGT1A3 UGT1A4 UGT1A5 UGT1A6 UGT1A7 UGT1A8 UGT1A9 UGT1A10 GAPDH

Human skin (Donor B)
Figure 2

A

![Graph showing Resorfin (pmol) vs Time (min)]

B

![Bar graph showing Fold induction of CYP1A1 vs Irradiated L-tryptophan (min)]

C

![Bar graph showing Fold induction of UGT1A1 vs Irradiated L-tryptophan (min)]
Figure 3

A

Fold induction of CYP1A1

C 0.1 1 5 10 50
FICZ (nM)

* indicates statistical significance

B

Fold induction

Control
FICZ 50 nM

UGT1A1  UGT1A4  UGT1A8

* indicates statistical significance

C

Fold induction of UGT1A1

C 0.1 1 5 10 50
FICZ (nM)

* indicates statistical significance
Figure 4

Estradiol 3-β-glucuronidation (pmol/min/mg)

Control  UV  FICZ

0  2  4  6  8

*  **
Figure 7

A

![Bar graph showing fold expression of UGT1A1](image)

B

![Image of gel with lanes labeled 1 to 8, showing expression of UGT1A1 and HLM under control and UV conditions](image)

C

![Bar graph showing fold change of UGT1A1 expression](image)